The idea of targeting cancer through multiple metabolic vulnerabilities is certainly compelling, and there is strong biological rationale for studying how tumor metabolism can be influenced. What I find particularly important, however, is distinguishing between a mechanistically plausible intervention and one that has demonstrated clinical benefit in humans.

Cancer is not a single metabolic disease, and tumors can be remarkably adaptable; often switching fuel sources and metabolic pathways in response to nutrient availability, treatment pressure, and changes in the tumor microenvironment. That makes the concept of a multi-lever approach intriguing, but also scientifically complex.

As a physician-scientist, I think the most valuable next step is to ask not only whether a metabolic intervention can affect cancer biology, but which patients, which tumor types, and under what metabolic context are most likely to benefit. The future of cancer metabolism may ultimately be less about a universal metabolic “stack” and more about precisely matching metabolic vulnerabilities to tumor biology, while ensuring that the evidence moves from compelling mechanism to rigorous clinical validation.

Thank you!